Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDF
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Change of perindopril (Coversyl) salt from erbumine to arginineChange of perindopril (Coversyl) salt from erbumine to arginine
Published 2006-08-01 00:00:00
The PBAC has approved the change of perindopril salt from erbumine to arginine. The decision was based on bioequivalence of the two formulations of the angiotensin-converting enzyme (ACE) inhibitor. The new salt has improved stability in high humidity but there is no change to the effectiveness of the medicine.
The new formulation is available on the PBS from 1 August. The old erbumine-based formulation will not be removed from the PBS until 1 December meaning there is a 4-month period where both formulations are available.
While such formulation changes are often inconsequential to how the medicine is used, in this case there are some differences that may cause confusion:
- Tablet strengths have changed slightly
- The 4-mg tablet has changed colour
- Packaging is now a small bottle rather than a blisterpack in a box.
The new product has retained its brand name — Coversyl — which may add to the potential for confusion by medicine users not expecting the appearance of the medicine to change.
The table shows the therapeutically equivalent doses of perindopril. Note there is no increase in dose in moving, for example, from perindopril erbumine 2 mg to perindopril arginine 2.5 mg.
| Perindopril arginine (new) | Perindopril erbumine (replaced) | |
|---|---|---|
| 2.5 mg (white, round) | = | 2.0 mg (white, round) |
| 5.0 mg (light green, rod-shaped) | = | 4.0 mg (white, rod-shaped) |
| 10.0 mg (dark green, round) | = | 8.0 mg (dark green, round) |
Finally, be aware that the fixed-strength combination tablets of perindopril with the diuretic, indapamide, (Coversyl Plus) will continue to contain the erbumine salt into 2007.
Date published: 2006-08-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
